ERBB2 and neoplasm: Finally, not all patients with HER2-positive tumours received anti-HER2 therapy in this cohort; some patients, including some older women with co-morbidities and those with small and node-negative HER2-positive tumours, were less likely to receive neoadjuvant anti-HER2 therapy.